在恰当的阶段针对恰当的靶点和药物进行检测。
Testing the right target and right drug at the right stage.
机构信息
Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02446, USA.
出版信息
Sci Transl Med. 2011 Nov 30;3(111):111cm33. doi: 10.1126/scitranslmed.3002609.
Abstract
Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?
摘要
阿尔茨海默病（AD）是唯一一种没有现有治疗方法的主要致死原因。最近在 AD 痴呆阶段的临床试验结果令人失望，这引发了人们对我们目前开发疾病修饰药物方法的诸多质疑。越来越多的证据表明，AD 的病理生理过程在痴呆症发病前多年就已经开始。那么，为什么我们还要在疾病末期的患者身上测试针对疾病早期阶段的药物呢？
相似文献
1
Testing the right target and right drug at the right stage.
Sci Transl Med. 2011 Nov 30;3(111):111cm33. doi: 10.1126/scitranslmed.3002609.
2
Pre-dementia Alzheimer's trials: overview.
J Nutr Health Aging. 2010 Apr;14(4):294. doi: 10.1007/s12603-010-0065-2.
3
Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.
Curr Drug Metab. 2018;19(8):704-713. doi: 10.2174/1389200219666180305152553.
4
[Drug development for overcoming dementia in Japan].
Rinsho Shinkeigaku. 2014;54(12):1181-3. doi: 10.5692/clinicalneurol.54.1181.
5
[Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
Nihon Rinsho. 2016 Mar;74(3):438-41.
6
[Toward Preclinical Trials for Alzheimer's Disease].
Brain Nerve. 2017 Jul;69(7):711-722. doi: 10.11477/mf.1416200812.
7
Advances in Alzheimer's disease drug development.
BMC Med. 2015 Mar 25;13:62. doi: 10.1186/s12916-015-0297-4.
8
Rethinking Alzheimer's disease therapy: are mitochondria the key?
J Alzheimers Dis. 2010;20 Suppl 2:S579-90. doi: 10.3233/JAD-2010-100327.
9
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61-74. doi: 10.3233/jad-2004-6s610.
10
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Pharmacol Res. 2005 Jan;51(1):1-17. doi: 10.1016/j.phrs.2004.05.005.
引用本文的文献
1
More fit KL-VS heterozygotes have more favorable AD-relevant biomarker profiles.
Alzheimers Dement (N Y). 2025 Aug 8;11(3):e70133. doi: 10.1002/trc2.70133. eCollection 2025 Jul-Sep.
2
Influence of age and sex on presymptomatic phases of neurodegenerative diseases: Focus on multiple sclerosis and Alzheimer's disease.
Rev Neurol (Paris). 2025 Aug 6. doi: 10.1016/j.neurol.2025.06.015.
3
An explainable transformer model for Alzheimer's disease detection using retinal imaging.
Sci Rep. 2025 Jul 23;15(1):26773. doi: 10.1038/s41598-025-12498-2.
4
Cognitive decline across five cognitive batteries: Sample size implications for clinical trials.
Alzheimers Dement (N Y). 2025 Jul 16;11(3):e70137. doi: 10.1002/trc2.70137. eCollection 2025 Jul-Sep.
5
Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions.
Ibrain. 2025 May 10;11(2):162-184. doi: 10.1002/ibra.12197. eCollection 2025 Summer.
6
The patient pathway for mild cognitive impairment due to Alzheimer's disease in Asia: Current practices, barriers, and expert recommendations for optimization.
J Prev Alzheimers Dis. 2025 Aug;12(7):100215. doi: 10.1016/j.tjpad.2025.100215. Epub 2025 Jun 6.
7
A brief history of Aβ imaging.
Alzheimers Dement. 2025 May;21(5):e70291. doi: 10.1002/alz.70291.
8
A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantification.
J Prev Alzheimers Dis. 2025 Aug;12(7):100186. doi: 10.1016/j.tjpad.2025.100186. Epub 2025 Apr 19.
9
Differential Expression of Disulfidptosis-Related Genes in Spinal Cord Injury and Their Role in the Immune Microenvironment.
Mol Neurobiol. 2025 Apr 16. doi: 10.1007/s12035-025-04931-4.
10
Limited generalizability and high risk of bias in multivariable models predicting conversion risk from mild cognitive impairment to dementia: A systematic review.
Alzheimers Dement. 2025 Apr;21(4):e70069. doi: 10.1002/alz.70069.
本文引用的文献
1
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.
Ann Neurol. 2012 Jun;71(6):765-75. doi: 10.1002/ana.22628. Epub 2012 Apr 9.
2
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.
Arch Neurol. 2012 Feb;69(2):198-207. doi: 10.1001/archneurol.2011.1538. Epub 2011 Oct 10.
3
Resolving controversies on the path to Alzheimer's therapeutics.
Nat Med. 2011 Sep 7;17(9):1060-5. doi: 10.1038/nm.2460.
4
Episodic memory decline predicts cortical amyloid status in community-dwelling older adults.
J Alzheimers Dis. 2011;27(3):627-37. doi: 10.3233/JAD-2011-110818.
5
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351.
6
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.
7
Amyloid-dependent and amyloid-independent stages of Alzheimer disease.
Arch Neurol. 2011 Aug;68(8):1062-4. doi: 10.1001/archneurol.2011.70. Epub 2011 Apr 11.
8
Amyloid-β associated cortical thinning in clinically normal elderly.
Ann Neurol. 2011 Jun;69(6):1032-42. doi: 10.1002/ana.22333. Epub 2011 Mar 17.
9
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.
Ann Neurol. 2011 Jan;69(1):181-92. doi: 10.1002/ana.22248.
10
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.
Alzheimers Res Ther. 2011 Jan 6;3(1):1. doi: 10.1186/alzrt59.
Zotero 插件